canagliflozin

Known as: Canagliflozin [Chemical/Ingredient] 
A C-glucoside with a thiophene ring that is an orally available inhibitor of sodium-glucose transporter 2 (SGLT2) with antihyperglycemic activity… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2017
Highly Cited
2017
 
Is this relevant?
Highly Cited
2015
Highly Cited
2015
OBJECTIVE This study assessed the incidence of serious adverse events of diabetic ketoacidosis (DKA) among patients with type 2… (More)
  • table 1
  • table 1
  • table 2
Is this relevant?
Highly Cited
2013
Highly Cited
2013
AIMS Canagliflozin is a sodium glucose co-transporter 2 inhibitor in development for type 2 diabetes mellitus (T2DM). The… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2013
Highly Cited
2013
BACKGROUND Sodium-glucose cotransporter 2 (SGLT2) inhibitors improve glycaemia in patients with type 2 diabetes by enhancing… (More)
Is this relevant?
Highly Cited
2013
Highly Cited
2013
AIMS Canagliflozin is a sodium glucose co-transporter 2 inhibitor in development for treatment of type 2 diabetes mellitus (T2DM… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2013
Highly Cited
2013
The aim of this work was to evaluate the efficacy and safety of canagliflozin vs placebo and sitagliptin in patients with type 2… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 2
Is this relevant?
Highly Cited
2013
Highly Cited
2013
OBJECTIVE To evaluate the efficacy and safety of canagliflozin, a sodium glucose cotransporter 2 inhibitor, compared with… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
Is this relevant?
Highly Cited
2013
Highly Cited
2013
AIMS Canagliflozin is a sodium glucose co-transporter 2 inhibitor developed for the treatment of type 2 diabetes mellitus (T2DM… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2012
Highly Cited
2012
OBJECTIVE To evaluate the effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, in type 2 diabetes mellitus… (More)
  • figure 1
  • figure 1
  • table 2
Is this relevant?
Highly Cited
2011
Highly Cited
2011
Canagliflozin, a potent, selective sodium glucose co-transporter 2 inhibitor in development for treatment of type 2 diabetes… (More)
  • figure 1
  • figure 2
Is this relevant?